Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

NCT05614063 is registered in ClinicalTrials.gov with Xenon Pharmaceuticals Inc. as lead sponsor.

NCT NCT05614063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05614063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Lead sponsor
Xenon Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 18, 2022
Completion date
February 3, 2026
Enrollment
380 (actual)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

focal onset seizures